Navigation Links
Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
Date:7/7/2008

BELLEVUE, Wash., July 7 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced that it has begun treatment of patients with benign prostatic hyperplasia (BPH), or enlargement of the prostate, using Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment under development. LSO plans to conduct a 12-patient, Phase I/II dose-escalation study at four sites in the United States as well as a 40-patient, Phase IIa study in Australia, expected to begin during the current quarter.

"Treating patients with this serious quality-of-life problem is an important milestone for our Litx technology," said Llew Keltner, M.D., Ph.D., President and Chief Executive Officer of LSO. "We plan to continue to demonstrate the broader applicability of Litx beyond oncology." LSO currently is conducting Phase III clinical studies of Litx in patients with hepatoma (primary liver cancer) and metastatic colorectal cancer and expects to initiate a Phase III clinical study in glioma in the second half of 2008.

BPH is a common result of aging and is estimated to occur in more than 14 million American men. BPH rarely causes symptoms before age 40, but more than half of men in their sixties and as many as 90 percent in their seventies and eighties have some symptoms of BPH, which typically include painful and frequent urination caused by the enlarged prostate's reduction of urine flow through the urethra. Early stage treatment is critical, because severe BPH can cause serious problems over time, such as urinary tract infections, bladder stones, incontinence, and eventually untreatable bladder or kidney damage.

Litx uses light-emitting diodes (LEDs) to activate LS11 (talaporfin sodium) molecules. Once activated, these molecules cause the production of singlet oxygen, which can kill target tissues with minimal side effects through vascular closure and apoptosis, or "programmed cell death." The single-use, disposable Litx device contains a tiny array of LEDs.

In the Litx BPH application, a modified standard urethral catheter positions the proprietary light-emitting LED array precisely within the prostate. After systemic injection of LS11, the LEDs are turned on, and activation of the drug occurs locally within the prostate. When the short treatment is complete, the LED-containing catheter is removed and thrown away. The goal of the therapy is to kill prostate tissue via apoptosis within a highly localized zone in the prostate, without causing inflammation. The short, single outpatient treatment is designed to effectively re-establish and maintain an unobstructed urine flow, relieving BPH symptoms.

ABOUT LIGHT SCIENCES ONCOLOGY

Light Sciences Oncology, Inc. (LSO) is developing Light Infusion Therapy(TM) (Litx(TM)) to provide safer and more effective treatment for cancer and other conditions. In addition to the Phase III trials in hepatocellular carcinoma and colorectal cancer metastatic to the liver, the Company has completed a Phase II clinical trial of Litx in glioma and plans to initiate a Phase III trial in glioma during the second half of 2008. LSO has widened the scope of potential therapeutic applications of the versatile Litx platform to include benign neoplasms such as benign prostatic hyperplasia (BPH), neurofibromas, and uterine fibroids, as well as vascular disease and dermatology. The Company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally talented team.

Light Infusion Therapy(TM) and Litx(TM) are trademarks of Light Sciences Oncology, Inc.

Contact:

Robert M. Littauer

Vice President, Chief Financial Officer and Treasurer

425-957-8900

bobl@lsoncology.com

Llew Keltner, M.D., Ph.D.

President and CEO

425-957-8900

dr_llew@lsoncology.com

website: http://www.lsoncology.com


'/>"/>
SOURCE Light Sciences Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
2. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
3. New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI
4. Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
5. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
6. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
9. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
10. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
11. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):